Systemic juvenile idiopathic arthritis–associated lung disease: A retrospective cohort study

Table 4 Main treatment outcomes of the patients with systemic juvenile arthritis and interstitial lung disease

No.	First biologic	Biologic at the ILD onset	Final therapy	Respiratory symptoms at the last follow-up visit	Dose reduction of non-biologic DMARDs	Dose reduction of BA	Discontinuation of GCS therapy	The outcome of sJIA-LD	The outcome of sJIA
1	TCZ	TCZ	CAN + ABT + CsA + GCS + SDF	No	No	No	No	Progression	Improvement
2	TCM	CAN	CAN + MMF + inhGS	No	Yes	No	Yes	Progression with the following improvement	Remission
3	CAN	CAN	TCZ + CsA	No	No	No	Yes	Improvement	Remission
4	TCZ	TCZ	CAN + MMF	No	No	No	Yes	Improvement	Improvement
5	TCZ	TCZ	CAN + GCS + IVIG	-	-	-	No	Death	Death

ABT: Abatacept; CAN: Canakinumab; CsA: Cyclosporine A; DMARD: Disease-modifying anti-rheumatic drug; GCS: Glucocorticosteroids; inhGCS: Inhaled glucocorticosteroids; IVIG: Intravenous immunoglobulin; ILD: Interstitial lung disease; SDF: Sildenafil; sJIA: Systemic juvenile idiopathic arthritis; TCZ: Tocilizumab.